Literature DB >> 8523557

Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.

L G Kostrikis1, Y Cao, H Ngai, J P Moore, D D Ho.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) M group strains have been assigned to date to nine distinct genetic subtypes, designated A through I, according to phylogenetic analyses of nucleotide sequences of their env or gag genes. Whether there is any relationship between phylogenetic subtypes and the neutralization serotypes is not clear, yet defining the nature of any such relationship by mathematical means would be of major importance for the development of globally effective HIV-1 vaccines. We have therefore developed a quantitative method to analyze serum neutralization of HIV-1 isolates and to identify HIV-1 neutralization serotypes. This method involves calculations of the neutralization index, N(i), a newly defined parameter derived from plots generated from in vitro neutralization assays, calculations of pairwise serum-virus vector distances, and cluster analyses. We have applied this approach to analyze three independent neutralization matrices involving primary HIV-1 strains and sera from genetic subtypes A, B, C, D, E, F, and I. Detailed serum and HIV-1 isolate cluster analyses have shown that in general, the identified neutralization serotypes do not directly correlate with HIV-1 genetic subtypes. These results suggest that neutralization serotypes do not during natural HIV-1 infection are not governed by antibodies directed against simple epitopes within gp120 monomers. A significant proportion (28%) of 1,213 combinations of sera and HIV-1 isolates caused serum-dependent infectivity enhancement [negative N(i) values] rather than neutralization. We also noted that negative N(i) values tended to correlate better with certain HIV-1 isolates rather than with HIV-1-positive sera. Syncytium-inducing variants of HIV-1 were slightly more likely than non-syncytium-inducing variants to undergo serum-dependent infectivity enhancement, although the latter variants could clearly be susceptible to enhancement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8523557      PMCID: PMC189833     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

2.  V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F.

Authors:  M G Morgado; E C Sabino; E G Shpaer; V Bongertz; L Brigido; M D Guimaraes; E A Castilho; B Galvão-Castro; J I Mullins; R M Hendry
Journal:  AIDS Res Hum Retroviruses       Date:  1994-05       Impact factor: 2.205

3.  Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil.

Authors:  E C Sabino; E G Shpaer; M G Morgado; B T Korber; R S Diaz; V Bongertz; S Cavalcante; B Galvão-Castro; J I Mullins; A Mayer
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

Authors:  B T Korber; K MacInnes; R F Smith; G Myers
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

5.  Molecular phylogeny of part of the env gene of HIV-1 strains isolated in Côte d'Ivoire.

Authors:  W Janssens; L Heyndrickx; Y Van de Peer; A Bouckaert; K Fransen; J Motte; G M Gershy-Damet; M Peeters; P Piot; G van der Groen
Journal:  AIDS       Date:  1994-01       Impact factor: 4.177

6.  Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype.

Authors:  O Dumitrescu; M L Kalish; S C Kliks; C I Bandea; J A Levy
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

Review 7.  A review of human immunodeficiency virus infection in India.

Authors:  M K Jain; T J John; G T Keusch
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-11

8.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses.

Authors:  M Grez; U Dietrich; P Balfe; H von Briesen; J K Maniar; G Mahambre; E L Delwart; J I Mullins; H Rübsamen-Waigmann
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  53 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee.

Authors:  P N Fultz; L Yue; Q Wei; M Girard
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China.

Authors:  Hong Shang; Xiaoxu Han; Xuanling Shi; Teng Zuo; Mark Goldin; Dan Chen; Bing Han; Wei Sun; Hao Wu; Xinquan Wang; Linqi Zhang
Journal:  J Biol Chem       Date:  2011-02-16       Impact factor: 5.157

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 10.  Introduction and immunopathogenesis of acquired immune deficiency syndrome.

Authors:  S Sudharshan; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2008 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.